Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
暂无分享,去创建一个
A. Jazaeri | M. Birrer | E. Ratner | H. Lankes | S. Bellone | A. Santin | N. Buza | W. Huh | M. Frumovitz | S. Khleif | R. O’Cearbhaill | W. Deng
[1] Huyi Liang,et al. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer , 2018, Journal of Cancer.
[2] J. Schellens,et al. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study. , 2018 .
[3] H. Rugo,et al. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Machiels,et al. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. , 2017 .
[5] Michael W Sill,et al. Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.
[6] Hong-wei Wang,et al. Increased expression of programmed death (PD)‐1 and its ligand PD‐L1 correlates with impaired cell‐mediated immunity in high‐risk human papillomavirus‐related cervical intraepithelial neoplasia , 2013, Immunology.
[7] Lieping Chen,et al. Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.
[8] Sheng Yao,et al. Advances in targeting cell surface signalling molecules for immune modulation , 2013, Nature Reviews Drug Discovery.
[9] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[10] S. H. van der Burg,et al. Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma , 2009, Clinical Cancer Research.
[11] B. Monk,et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Siegel,et al. Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial , 2007, Journal of Virology.
[13] S. Bellone,et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. , 2006, Gynecologic oncology.
[14] G. Parham,et al. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. , 2002, The New England journal of medicine.
[15] G. Parham,et al. Induction of Human Papillomavirus-Specific CD4+ and CD8+ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer , 1999, Journal of Virology.
[16] T T Chen,et al. Optimal flexible designs in phase II clinical trials. , 1998, Statistics in medicine.
[17] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.